We compared the in-vitro antimycobacterial activities of rifabutin and KRM-1648, two rifamycin derivatives, with that of rifampicin against 163 strains of Mycobacterium tuberculosis. We also evaluated the correlation between the level of resistance to rifampicin, rifabutin and KRM-1648 and genetic alterations in the rpoB gene. 
Introduction
From the late 1980s, after decades in steady decline, tuberculosis (TB) has again become a problem throughout the world. At present, approximately 1.7 billion individuals, or one-third of the world's population, are infected with Mycobacterium tuberculosis. In 1990 alone, there were an estimated 2.9 million deaths due to TB. 1 Major factors contributing to the resurgence of TB include the growing rate of HIV infection, poor housing, overcrowding and migration. 2 Of these factors, HIV infection is the most potent risk factor for the development of active TB. Furthermore, the recent emergence of multidrugresistant TB is another serious problem in certain patients, [3] [4] [5] resulting in high mortality rates. [6] [7] [8] The development of more active and safe antituberculous agents as alternatives to rifampicin and isoniazid is therefore of high priority.
Rifabutin, a spiro-piperidyl rifamycin, and KRM-1648 (benzoxazinorifamycin) are rifamycin derivatives which are more active than rifampicin against slow-growing mycobacteria, including M. tuberculosis and Mycobacterium avium-intracellulare complex (MAC), in vitro and in vivo. [9] [10] [11] [12] [13] [14] [15] [16] [20] [21] [22] [23] In the present study, we determined the MICs of rifampicin, rifabutin and KRM-1648 for M. tuberculosis strains to determine the correlation between the level of resistance and specific genetic alterations in the rpoB gene.
Materials and methods

Susceptibility testing
Test drugs. Rifampicin (Daiichi Pharmaceutical Co., Tokyo, Japan), rifabutin (Pharmacia, Milan, Italy) and KRM-1648 (Kaneka Co., Osaka, Japan) were used in the present study. They were dissolved in dimethyl sulphoxide at 20,480 mg/L and stored at -70°C. Working solutions were prepared from the stock solutions by dilution with Middlebrook 7H9 broth containing ADC supplement (Difco, Detroit, MI, USA).
Mycobacterial strains. One hundred and sixty-three strains of M. tuberculosis were examined. All strains were isolated from different patients with TB at Nagasaki University Hospital and affiliated hospitals mainly located in the western part of Japan. These patients were unrelated and >80% of them had been previously treated with anti-tuberculosis drugs. The standard strain of M. tuberculosis, H37Rv, was used as a control.
Determination of MIC.
The MIC of each test drug for all isolates was determined by the microdilution method using 7H9 broth as described previously. 24 Briefly, 100 L of serial two-fold dilutions of these drugs (used at 17 concentrations ranging from 0.016 to 1024 mg/L) were dispensed into each well of a 96-well microtitre plate (Cell Wells 25850, Corning Glass, Corning, NY, USA), followed by storage at -70°C until use. All strains were initially precultured in 15 mL of 7H9 broth at 37°C for 1-2 weeks, the suspension of organisms was then adjusted to a McFarland 0.5 standard corresponding to approximately 2-5 10 7 cfu/mL. Finally, 100 L of bacterial suspension was inoculated into each well to create a final concentration of test drugs ranging from 0.008 to 512 mg/L. The plates were sealed in plastic boxes and incubated at 37°C in a moisturized incubator. When growth was observed in the drug-free wells, MICs were defined as the lowest drug concentration at which no visible growth was noted. The incubation was continued for 21 days and the MICs were determined again in order to exclude false negative results. Strains with rifampicin MICs > 1 mg/L were considered resistant.
Detection of genetic alterations in the rpoB gene
DNA preparation and identification of M. tuberculosis. M. tuberculosis DNA was extracted from bacterial colonies maintained on Ogawa egg medium using phenol and chloroform as reported previously. 25 Ten nanograms of each DNA sample was used to amplify, by PCR, the M. tuberculosis targeting protein antigen b (pab) gene to confirm the identification of all the tested strains. The PCR products were electrophoresed in 2% agarose gels, stained with ethidium bromide and visualized by UV transillumination. A positive control (H37Rv strain) and a negative control (deionized distilled water) were included in each step beginning from extraction of DNA to sequencing of the rpoB gene in every 10-sample experiment.
Sequencing of the 69 bp core region of the rpoB gene. PCR-direct sequencing analysis was employed using 10 ng of M. tuberculosis DNA. The oligonucleotide primers used to amplify the rpoB gene were identical to those described previously, 26 which amplify a 255 bp fragment of the rpoB gene including the entire 69 bp core region. PCR was performed using 12.5 pmol of the primer and 50 L of the PCR mixture (50 mM KCl, 10 mM Tris-HCl, 1.5 mM MgCl 2 , 10 mg/L gelatin, 0.25 mM of each deoxynucleotide triphosphate, and 1.25 U Taq polymerase (Takara Shuzo, Otsu, Japan)). Amplification was performed in a PerkinElmer 9600 DNA thermal cycler (Perkin-Elmer Medical Instruments, Pomona, CA, USA), using a program identical to that described in our previous report. 26 These PCR products were then precipitated by adding two volumes of isopropanol, an equal volume of 5 M ammonium acetate and 5 L of 2000 mg/L glycogen (Boehringer-Mannheim, Mannheim, Germany) followed by centrifugation for 10 min. Pellets were washed with 70% ethanol and redissolved in 50 L of 0.1 TE buffer (10 mM Tris-HCl, 1.0 mM EDTA; pH 8.0). Subsequently, a cycle sequencing reaction was performed using 4 L of redissolved PCR product solution with a Sequence HighPlus kit (NRS-210, Toyobo, Osaka, Japan) according to the protocols recommended by the manufacturer with 5 pmol of sequencing primer. The sequencing reaction was performed on both strands using primers described previously. 26 Three microlitres of each aliquot of sequencing reaction mixture were electrophoresed in a 6% polyacrylamide sequencing gel (40 cm 20 cm 0.35 mm) with 30 W constant power for about 2 h, then transferred on to positively charged nylon membrane (NRS-204; Toyobo) by overnight blotting. Finally, sequence analysis was performed using a non-radioisotopic detection kit (Imaging High-Chemilumi kit, NRS-203; Toyobo).
Results
MICs of rifampicin, rifabutin and KRM-1648 for M. tuberculosis strains
The susceptibility of the test strains of M. tuberculosis to rifampicin, rifabutin and KRM-1648 is summarized in Figure 1 . The ranges of MICs of these drugs were as follows: rifampicin, 0.03->512 mg/L; rifabutin, 0.015-64 mg/L; KRM-1648, 0.008-512 mg/L. Although the cumulative percentage curves of these antituberculous drugs were similar, rifampicin showed the weakest antituberculous activity. Reference strain H37Rv and about 53% of the test strains were susceptible to 1 mg/L of rifabutin and KRM-1648, while 43% of the strains were sensitive to the same concentration of rifampicin. Rifabutin showed at least four times more activity than KRM-1648 in strains with rifampicin MIC > 4 mg/L.
The correlation between MICs of these three drugs for test strains was analysed in detail ( Figure 2 ). (96.6%) of the 87 strains with rifabutin MICs of 1 mg/L, the MIC of KRM-1648 was two-to eight-fold lower than the MIC of rifabutin. For seventy-four (97.4%) of the 76 strains with MICs of rifabutin of 2 mg/L, the MIC of KRM-1648 was two-to eight-fold higher than the MIC of rifabutin.
Genetic alterations
PCR products of the pab gene were obtained from all 163 strains, confirming all as M. tuberculosis (data not shown). The genetic alterations and frequencies are summarized in Figure 3 and the Table. Of the 163 strains, 92 had genetic alterations: 84 strains had a single point mutation, four (nos 77, 101, 120 and 121) had double point mutations, one (no. 81) had an insertion, and three (nos 80, 137 and 138) had deletions. The frequencies of amino acid alterations in codons 516, 526 and 531 were 7%, 20% and 60%, respectively. Fifty-one isolates had the same point mutation at codon 531 (TCG (Ser) TTG (Leu)). Mutation of codon 510 was detected in two strains (nos 120 and 121) with double mutation. Altogether, genetic alterations were found at 11 amino acid positions around the 69 bp core region studied here.
Relationship between MICs of rifampicin, rifabutin and KRM-1648 against 163 M. tuberculosis strains, and position and type of genetic alteration
All 70 rifampicin-susceptible strains were also susceptible to rifabutin and KRM-1648. Of these, mutations were detected in only four strains (nos 62, 63, 67 and 70), at codon 515, 521 or 533; these alterations did not influence the susceptibility to rifampicin, rifabutin and KRM-1648.
Of the 93 strains resistant to rifampicin (MIC 2 mg/L), 17 were susceptible to both rifabutin and KRM-1648 with MICs 1 mg/L. Genetic alterations were observed in all except five of these strains, in codons 514, 516, 518, 526, 529 and 531. Alterations in codons 514, 516, 518 and 529 mainly influenced the susceptibility to rifampicin, but not that to rifabutin and KRM-1648.
All except two of the 76 strains resistant to all three drugs had genetic alterations in codon 510, 513, 526 or 531. All 58 of the strains with a point mutation at codon 513 or 531 were highly resistant to rifampicin (MIC 64 mg/L), and all except one strain were also highly resistant to rifabutin ( Two strains, nos. 80 (with a 3 bp deletion that replaced one amino acid at codon 518) and 81 (with a 3 bp insertion at codon 514), were resistant to rifampicin (MIC 16 mg/L), but showed low MICs to rifabutin and KRM-1648. Two other strains (nos. 137 and 138) with a 9 bp deletion that replaced three consecutive amino acids (codons 515-517) were also resistant to the three agents with MICs 32 mg/L.
Discussion
The high incidence of multidrug-resistant TB has highlighted the need for new and effective antituberculous drugs. Many investigators have already confirmed that rifabutin and KRM-1648 are more active then rifampicin, against M. tuberculosis, with some crossresistance between rifabutin, KRM-1648 and rifampicin. [27] [28] [29] However, only a few have examined the relationship between the susceptibility to rifabutin and KRM-1648 and genetic alterations in the M. tuberculosis rpoB gene. 28 In this study, we determined the specific nature of the rifabutin, KRM-1648 and rifampicinresistance in 163 test strains by rpoB gene sequencing.
The present in-vitro studies showed that all 70 strains susceptible to rifampicin were also susceptible to rifabutin and KRM-1648, but that none of the rifabutin-or KRM-1648-resistant strains were susceptible to rifampicin. Twelve strains of M. tuberculosis resistant to rifampicin with MICs 16 mg/L were also susceptible to rifabutin and KRM-1648 with MICs 1 mg/L. In these strains, rifabutin and KRM-1648 demonstrated better in-vitro activity than rifampicin, and KRM-1648 exhibited more activity than rifabutin. Seventy-six of 81 rifampicinresistant strains with MICs 32 mg/L were also resistant to rifabutin and KRM-1648, but showed lower MICs. In addition, rifabutin exhibited a better activity than KRM-1648 in these strains.
Although the exact mechanism of antimycobacterial activity of rifamycin derivatives is not clearly known, it is thought that the outer cell membrane of the microrganism acts as a permeability barrier for hydrophobic agents. 30 Since KRM-1648 is more hydrophobic than rifampicin, it may be able to penetrate better into mycobacterial cytoplasms. 30, 31 Several studies have reported that rifabutin acts by inhibiting RNA polymerase in rifampicinsusceptible M. tuberculosis, but this is explained by inhibition of the uptake of thymidine into bacterial DNA in rifampicin-resistant bacteria. 12, 18, 27 Our study revealed that genetic alterations were present in 95% of rifampicin-resistant strains, consistent with data reported by other investigators. 21, 22, 32 Furthermore, the levels of resistance to the three test drugs were dependent on the type of mutation involved. For example, all but one strain (98%) containing mutations located at amino acid positions 513 or 531 of the rpoB gene were resistant to rifampicin, rifabutin and KRM-1648. Similarly, mutations at codon 516 or 529, a deletion at codon 518, and an insertion at codon 514 were associated with resistance to rifampicin but not to rifabutin or KRM-1648. On the other hand, mutations at positions 515, 521 and 533 did not influence the MICs of the three test drugs. Our results also demonstrated that the activity of rifabutin and KRM-1648 against M. tuberculosis depends not only on the mutation position, but also on the type of substitutions in the rpoB gene. For example, of the 18 strains with seven different missense mutations at codon 526, those with substitutions by glycine, glutamine or leucine were resistant to rifampicin, but susceptible to rifabutin and KRM-1648. In contrast, strains with substitutions by tyrosine, proline, arginine or aspartic acid were resistant to all three agents. Whether genetic alterations at codon 510 influence susceptibility is not clear at present, as this mutation appeared in a double point mutation with 526 in our study.
No genetic alteration was detected in five rifampicinresistant strains with MICs 2 mg/L of rifabutin and KRM-1648. The existence of these strains might indicate that there are additional clusters of mutations or another target site of rifampicin located outside the core region of rpoB, such as codons 687 and 146 described in Escherichia coli. 33, 34 However, the finding that there are resistant strains without mutations, even in other regions of the rpoB gene and including those where amino acid changes have been associated with rifampicin resistance in E. coli, might suggest additional molecular mechanisms such as alterations in permeability or mutations in other RNA polymerase subunits. 35 In this study, we found that rifabutin and KRM-1648 were more active in vitro against M. tuberculosis than rifampicin. We also found that 8% of rifampicin-resistant strains were also susceptible to rifabutin and KRM-1648; although this ratio is lower than that reported by other investigators, 17, 19, 36 this finding suggests that rifabutin and KRM-1648 may be useful against infections caused by rifampicin-resistant M. tuberculosis, as suggested in mice. 10, 29 Our results also suggest that characterization of the genetic alterations in the rpoB gene may provide important information for selecting an appropriate rifamycin derivative for chemotherapy.
